Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | JMJD6 | Q6NYC1 | 1/20 | 0.43 |
| ▸ | STAT3 | P40763 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10565234 | 0.93 | KMT2A (0.46) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL10518392 | 0.90 | KMT2A (0.43) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL10432843 | 0.89 | KMT2A (0.43) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL9031091 | 0.87 | KMT2A (0.41) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL9032443 | 0.86 | KMT2A (0.41) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL6200613 | 0.85 | KMT2A (0.45) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL539020 | 0.85 | KMT2A (0.56) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL6201155 | 0.85 | THRB (0.45) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL537865 | 0.85 | MAPT (0.49) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL9031289 | 0.85 | GAA (0.41) | KMT2AMEN1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8598159-B2 | Therapeutic pyrazoloquinoline derivatives | DART NEUROSCIENCE (CAYMAN) LTD. (KY) | 2013-12-03 | — | — | US | disclosed |
| US-8349867-B2 | Quinoline compounds, intermediates, preparation methods and uses thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2013-01-08 | — | — | US | disclosed |
| EP-2166852-B1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS INC (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2011-03-17 | — | — | US | disclosed |
| US-20110046379-A1 | Quinoline Compounds, Intermediates, Preparation Methods and Uses Thereof | SHANGHAI INSTITUTE OF PHARMACEUTICAL INDUSTRY (CN) | 2011-02-24 | — | — | US | disclosed |
| US-7872002-B2 | Therapeutic pyrazoloquinoline derivatives | HELICON THERAPEUTICS, INC. (US) | 2011-01-18 | — | — | US | disclosed |
| EP-2166852-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | Helicon Therapeutics, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2008154438-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | HELICON THERAPEUTICS, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| EP-1042295-B1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN CO LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6093732-A | PREVENT HERPESVIRAL INFECTIONS, PARTICULARLY, HUMAN CYTOMEGALOVIRAL INFECTION | PHARMACIA & UPJOHN COMPANY (US) | 2000-07-25 | — | — | US | disclosed |
| WO-1999032450-A1 | 4-HYDROXYQUINOLINE-3-CARBOXAMIDES AND HYDRAZIDES AS ANTIVIRAL AGENTS | PHARMACIA & UPJOHN COMPANY (US) | 1999-07-01 | — | — | WO | disclosed |
| US-5889009-A | ADMINISTERING 1,7-DISUBSTITUTED-4-OX-3-(QUINOLINECARBOXYLIC ACID OR NAPHTHYRIDINECARBOXYLIC ACID) | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1999-03-30 | — | — | US | disclosed |
| EP-0614664-B1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1998-09-16 | — | — | EP | disclosed |
| US-5703081-A | CELL ADHESION INHIBITORS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-12-30 | — | — | US | disclosed |
| US-5519024-A | CELL ADHESION INHIBITOR | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-05-21 | — | — | US | disclosed |
| EP-0614664-A1 | Quinolonecarboxylic acid derivatives, their preparation and their use as cell adhesion inhibitors | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-09-14 | — | — | EP | disclosed |
| US-4870182-A | 4-Hydroxy-quinoline-3-carboxylic | BAYER AKTIENGESELLSCHAFT (DE) | 1989-09-26 | — | — | US | disclosed |
| US-4816451-A | Antibacterial 1,8-bridged 4-quinolonecarboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1989-03-28 | — | — | US | disclosed |
| US-4804760-A | Process for the preparation of 4-hydroxy-quinoline-3-carboxylic acids | BAYER AKTIENGESELLSCHAFT (DE) | 1989-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046379-A1 | Quinoline Compounds, Intermediates, Preparation Methods and Uses Thereof | HMGCR, PCSK9, ACAT2 | KMT2A 974/4885MEN1 3105/4885MAPT 1726/4885 |
| US-20080306049-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | KMT2A 2970/4885MEN1 3172/4885MAPT 461/4885 |
| US-20110065693-A1 | THERAPEUTIC PYRAZOLOQUINOLINE DERIVATIVES | GABRA5, GABRB1, GABRB2 | KMT2A 2970/4885MEN1 3172/4885MAPT 461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.